iStock_69856585_LARGE

PUBBLICAZIONI 2014

 

Iurlo A., Fracchiolla N., *Ferla V., Cassin R., Gottardi E., Beghini A., Gianelli U., Spinelli O., Cortelezzi A.

Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified.

J CLIN ONCOL 2014; 32(10): e37-e39.

________________________________________

Giordano R., Canesi M., Isalberti M., Isaias I.U., Montemurro T., Viganò M., Montelatici E., Boldrin V., Benti R., Cortelezzi A., Fracchiolla N., Lazzari L., Pezzoni G.

Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study.

J TRANSL MED 2014; 12(): 14-14.

________________________________________

Foà R., Del Giudice I., Cuneo A., Del Poeta G., Ciolli S., Di Raimondo F., Lauria F., Cencini E., Rigolin G.M., Cortelezzi A., Nobile F., Callea V., Brugiatelli M., Massaia M., Molica M., Trentin L., Rizzi R., Specchia G., Di Serio F., Orsucci L., Ambrosetti A., Montillo M., Zinzani P.L., Ferrara F., Morabito F., Mura M.A., Soriani S., Peragine N., Tavolaro S., Bonina S., Marinelli M., De Propris M.S., Starza I.D., Piciocchi A., Alietti A., Runggaldier E.J., Gamba E., Mauro F.R., Chiaretti S., Guarini A.

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.

AM J HEMATOL 2014; 89(5): 480-486.

________________________________________

Barcellini W., Imperiali F., Zaninoni A., Reda G., Consonni D., Fattizzo B., Lonati S., Nobili L., Zanella A., Cortelezzi A.

Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression.

LEUK LYMPHOMA 2014; 55(8): 1768-1773.

________________________________________

Visco C., Cortelezzi A., Moretta F., Falisi E., Maura F., Finotto S., Barcellini W., Ambrosetti A., Neri A., Ruggeri M., Rodeghiero F.

Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?

LEUK LYMPHOMA 2014; 55(6): 1261-1265.

________________________________________

D’Arena G., Laurenti L., Coscia M., Cortelezzi A., Chiarenza A., Pozzato G., Vigliotti M.L., Nunziata G., Fragasso A., Villa M.R., Grossi A., Selleri C., Deaglio S., La Sala A., Del Poeta G., Simeon V., Aliberti L., De Martino  L., Giudice A., Musto P., De Feo V.

Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey.

LEUK LYMPHOMA 2014; 55(4): 841-847.

________________________________________

Tadmor T., Bari A., Sacchi S., Marcheselli L., Liardo E.V., Avivi I., Benyamini N., Attias D., Pozzi S., Cox M.C., Baldini L., Brugiatelli M., Federico M., Polliack A.

Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era

HAEMATOL-HEMATOL J 2014; 99(1): 125-130.

________________________________________

Mauro F.R., Molica S., Laurenti L., Cortelezzi A., Carella A.M., Zaja F., Chiarenza A., Angrilli F., Nobile F., Marasca R., Musolino C., Brugiatelli M., Piciocchi A., Vignetti M., Fazi P., Gentile G., De Propris M.S., Starza I.D., Marinelli M., Chiaretti S., Del Giudice I., Nanni M., Albano F., Cuneo A., Guarini A., Foà R., GIMEMA G.

Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

LEUKEMIA RES 2014; 38(2): 198-203.

________________________________________

Iurlo A., Ubertis A., Artuso S., Bucelli C., *Radice T., Zappa M., Cattaneo D., Mari D., Cortelezzi A.

Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients

EUR J INTERN MED 2014; 25(1): 63-66.

________________________________________

Cortelezzi A., *Sciumè M., Liberati A.M., Vincenti D., Cuneo A., Reda G., Laurenti L., Zaja F., Marasca R., Chiarenza A., Gritti G., Orsucci L., Storti S., Angelucci E., Cascavilla N., Gobbi M., Mauro F.R., Morabito F., Fabris S., Piciocchi A., Vignetti M., Neri A., Rossi D. , Giannarelli D., Guarini A., Foà R.

Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.

LEUKEMIA 2014; 28(3): 642-648.

________________________________________

Tortorano A.M., Prigitano A., Esposto M.C., Arsic Arsenijevic V., Kolarovic J., Ivanovic D., Paripovic L., Klingspor L., Nordoy I., Hamal P., Arikan Akdagli S., Ossi C., Grancini A., Cavanna C., Lo Cascio G., Scarparo C., Candoni A., Caira M., Drogari Apiranthitou M., Working Group E., Boschetti C.

European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe.

EUR J CLIN MICROBIOL 2014; 33(9): 1623-1630.

________________________________________

Barcellini W.

Haemostasis and immunity: cross-talking systems?

BLOOD TRANSFUS 2014; 12(suppl 1 ): s348-s349.

________________________________________

Bari A., Tadmor T., Sacchi S., Marcheselli L., Cox C., Liardo E.V., Pozzi S., Benyamini N., Avivi I., Ferrari A., Baldini L., Falorio S., Gobbi P., Federico M., Polliack A.

Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy.

BRIT J HAEMATOL 2014; 167(1): 133-136.

________________________________________

Musto P., Simeon V., Martorelli M.C., Petrucci M.T., Cascavilla N., Di Raimondo F., Caravita T., Morabito F., Offidani M., Olivieri A., Benevolo G., Mina R., Guariglia A., D’Arena G., Mansueto G., Filardi N., Nobile F., Levi A., Falcone A., Cavalli M., Pietrantuono G., Villani O., Bringhen S., Omedè P., Lerose R., Agnelli L., Todoerti K., Neri A., Boccadoro M., Palumbo A.

Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.

LEUKEMIA 2014; 28(1): 222-225.

________________________________________

Duarte R.F., Boumendil A., Onida F., Gabriel I., Arranz R., Arcese W., Poiré X., Kobbe G., Narni F., Cortelezzi A., Olavarria E., Schmitz N., Sureda A., Dreger P.

Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis.

J CLIN ONCOL 2014; 32(29): 3347-3348.

________________________________________

Bassan R., Spinelli O., Oldani E., Intermesoli T., Tosi M., Peruta B., Borlenghi E., Pogliani EM., Di Bona E., Cassibba V., Scattolin A.M., Romani C., Ciceri F., Cortelezzi A., Gianfaldoni G., Mattei D., Audisio E., Rambaldi A.

Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia.

BLOOD CANCER J 2014; 4(7): e225-e225.

________________________________________

Iurlo A., Gianelli U., Rapezzi D., Cattaneo D., Fermo E., *Binda F., Santambrogio E., Bucelli C., Cortelezzi A.

Imatinib and ruxolitinib association: first experience in two patients.

HAEMATOL-HEMATOL J 2014; 99(6): e76-e77.

________________________________________

Mian M., Kwee I., Rinaldi A., Ponzoni M., Bhagat G., Rossi D. , Arcaini L., Gascoyne R., Mollejo M., Baldini L., Thieblemont C., Gaidano G., Zucca E., Bertoni F.

Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas.

BRIT J HAEMATOL 2014; 164(6): 896-899.

________________________________________

Fattizzo B., *Radice T., Cattaneo D., Pomati M., Barcellini W., Iurlo A.

Three Hematologic Malignancies in the Same Patient: Chronic Lymphocytic, Followed by Chronic Myeloide Leukemia and Acute Myeloide Leukemia.

CLIN LAB 2014; 60(): 1929-1932.

________________________________________

Tripodi A., Capaccio P., Pignataro L., Chantarangkul V., Menegatti M. , Bamonti F., Clerici M., De Giuseppe R., Peyvandi F.

Thrombin generation in patients with idiopathic sudden sensorineural hearing loss.

THROMB RES 2014; 133(6): 1130-1134.

________________________________________

Fulgenzi A., De Giuseppe R., Bamonti F., Ferrero M.E.

RIVISTA CENSITA CON I.F.= 0 – Improvement of oxidative and metabolic parameters by cellfood administration in patients affected by neurodegenerative diseases on chelation treatment.

BIOMED RES INT 2014; 2014(): 281510-281

________________________________________

Rondelli T., Risitano A.M., Peffault de Latour R., Sica M., Peruzzi B., Ricci P., Barcellini W., Iori A.P., Boschetti C., Valle V., Frémeaux Bacchi V. , Angioletti M., Socie G., Luzzatto L., Notaro R.

Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

HAEMATOL-HEMATOL J 2014; 99(2): 262-266.

________________________________________

Tripputi P., Bianchi P., Fermo E., Bignotto M., Zanella A.

Chromosome 7q31.1 deletion in myeloid neoplasms.

HUM PATHOL 2014; 45(2): 368-371.

________________________________________

Zanella A., Barcellini W.

Treatment of autoimmune hemolytic anemias.

HAEMATOL-HEMATOL J 2014; 99(10): 1547-1554.

________________________________________

Della Porta M.G., Alessandrino E.P., Bacigalupo A., Van Lint M.T., Malcovati L., Pascutto C., Falda M., Bernardi M., Onida F., Guidi S., Iori A.P., Cerretti R., Marenco P., Pioltelli P., Angelucci E., Oneto R., Ripamonti F.,  Bernasconi P., Bosi A., Cazzola M. , Rambaldi A., Gruppo Italiano Trapianto di Midollo Osseo G.

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.

BLOOD 2014; 123(15): 2333-2342.

________________________________________

Mariotti J., Maura F., Spina F., Roncari L., Dodero A., Farina L., Montefusco V., Carniti C. , Sarina B., Patriarca F., Rambaldi A., Onida F., Olivieri A., Zallio F., Corradini P.

Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.

BIOL BLOOD MARROW TR 2014; 20(6): 885-890.

________________________________________

Girmenia C., Raiola A.M., Piciocchi A., Algarotti A., Stanzani M., Cudillo L., Pecoraro C., Guidi S., Iori A.P., Montante B., Chiusolo P., Lanino E., Carella A.M., Zucchetti E., Bruno B., Irrera G., Patriarca F., Baronciani D., Musso M., Prete A., Risitano A.M., Russo D., Mordini N., Pastore D., Vacca A., Onida F., Falcioni S., Pisapia G., Milone G., Vallisa D., Olivieri A., Bonini A., Castagnola E., Sica S., Majolino I., Bosi A., Busca A., Arcese W., Bandini G., Bacigalupo A., Rambaldi A., Locasciulli A.

Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

BIOL BLOOD MARROW TR 2014; 20(6): 872-880.

________________________________________

Morris C., De Wreede L., Scholten M., Brand R., Van Biezen A., Sureda A., Dickmeiss E., Trneny M., Apperley J., Chiusolo P., Van Imhoff G.W., Lenhoff S., Martinelli G., Hentrich M., Pabst T., Onida F., Quinn M., Kroger N., De Witte T., Ruutu T., Chronic Malignancies and Lymphoma Working Parties of E.

Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide.

TRANSFUSION 2014; 54(10): 2514-2522.

________________________________________

Onida F., Brand R., Van Biezen A., Schaap M., Von dem Borne P.A., Maertens  J., Beelen D.W., Carreras E., Alessandrino E.P., Volin L., Kuball J.H., Figuera A., Sierra J., Finke J., Kroger N., De Witte T., subcommitte of the EBMT – CMWP M.

Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrosp

HAEMATOL-HEMATOL J 2014; 99(10): 1582-1590.

________________________________________

Arcaini L., Vallisa D., Rattotti S., Ferretti V.V., Ferreri A.J., Bernuzzi P., Merli M., Varettoni M., Chiappella A., Ambrosetti A., Tucci A., Rusconi C., Visco C., Spina M., Cabras G., Luminari S., Tucci M., Musto P., Ladetto M., Merli F., Stelitano C., D’Arco A., Rigacci L., Levis A., Rossi D. , Spedini P., Mancuso S., Marino D., Bruno R., Baldini L., Pulsoni A.

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.

ANN ONCOL 2014; 25(7): 1404-1410.

________________________________________

Augello C., Gianelli U., Savi F., Moro A., Bonoldi E., Gambacorta M., Vaira V., Baldini L., Bosari S.

MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma.

J CLIN PATHOL 2014; 67(8): 697-701.

________________________________________

Caltagirone S., Ruggeri M., Aschero S., Gilestro M., Oddolo D., Gay F., Bringhen S., Musolino C., Baldini L., Musto P., Petrucci M.T., Gaidano G., Passera R., Bruno B., Palumbo A., Boccadoro M., Omedè P.

Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.

HAEMATOL-HEMATOL J 2014; 99(10): 1611-1617.

________________________________________

Tacchetti P., Terragna C., Galli M., Zamagni E., Petrucci M.T., Pezzi A., Montefusco V., Martello M., Tosi P., Baldini L., Peccatori J., Ruggeri M., Pantani L., Lazzaro A., Elice F., Rocchi S., Gozzetti A., Cavaletti G., Palumbo A., Cavo M.

Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.

AM J HEMATOL 2014; 89(12): 1085-1091.

________________________________________

Bulian P., Shanafelt T.D., Fegan C., Zucchetto A., Cro L., Nuckel H., Baldini L., Kurtova A.V., Ferrajoli A., Burger J.A., Gaidano G., Del Poeta G., Pepper C., Rossi D., Gattei V.

CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.

J CLIN ONCOL 2014; 32(9): 897-904.

________________________________________

Ferreri A.J., Ciceri F., Brandes A.A., Montanari M., Balzarotti M., Spina M., Ilariucci F., Zaja F., Stelitano C., Bobbio F., Corazzelli G., Baldini L., Reni M.

MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.

NEUROLOGY 2014; 82(15): 1370-1373.

________________________________________

Corradini P., Vitolo U., Rambaldi A., Miceli R., Patriarca F., Gallamini A., Olivieri A., Benedetti E., Todeschini G., Rossi G., Salvi F., Bruno B., Baldini L., Ferreri A., Patti C., Tarella C., Pileri S., Dodero A.

Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma.

LEUKEMIA 2014; 28(9): 1885-1891.

________________________________________

Efficace F., Rosti G., Cottone F., Breccia M., Castagnetti F. , Iurlo A., Mandelli F., Baccarani M.

Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.

LEUKEMIA RES 2014; 38(3): 294-298.

________________________________________

Malagola M., Breccia M., Skert C., Cancelli V., Soverini S., Iacobucci I., Cattina F., Liberati A.M., Tiribelli M. , Annunziata M., Trabacchi E., de Vivo A., Castagnetti F. , Martinelli G., Fogli M., Stagno F., Pica G., Iurlo A., Pregno P., Abruzzese E., Pardini S., Bocchia M. , Russo S., Pierri I., Lunghi M., Barulli S., Merante S., Mandelli F., Alimena G., Rosti G., Baccarani M., Russo D.

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.

AM J HEMATOL 2014; 89(2): 119-124.

________________________________________

Gianelli U., Bossi A., Cortinovis I., Sabattini E., Tripodo C., Boveri E., Moro A., Valli R., Ponzoni M., M Florena A., F. Orcioni G., Ascani S., Bonoldi E., Iurlo A., Gugliotta G., Franco V.

Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.

MODERN PATHOL 2014; 27(6): 814-822.

________________________________________

Randi M.L., Bertozzi I., Rumi E., Elena C., Finazzi G., Vianelli N., Polverelli N., Ruggeri M., Vannucchi A.M., Antonioli E., Lussana F., Tieghi A., Iurlo A., Elli E., Ruella M., Fabris F. , Cazzola M. , Barbui T.

Pregnancy complications predict thrombotic events in young women with essential thrombocythemia.

AM J HEMATOL 2014; 89(3): 306-309.

________________________________________

Fraquelli  M., Giunta M., Pozzi R., Rigamonti C., Della Valle S., Massironi S., Conti C.B., Aghemo A., Ronchi G., Iurlo A., Primignani M. , Conte D., Colombo M.

Feasibility and reproducibility of spleen transient elastography and its role in combination with liver transient elastography for predicting the severity of chronic viral hepatitis.

J VIRAL HEPATITIS 2014; 21(2): 90-98.

________________________________________

Gianelli U., Iurlo A., Cattaneo D., Lambertenghi Deliliers G.

Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.

EXPERT REV HEMATOL 2014; 7(2): 255-264.

________________________________________

Breccia M., Luciano L., Latagliata R., Castagnetti F. , Ferrero D., Cavazzini F., Trawinska M.M., Annunziata M., Stagno F., Tiribelli M. , Binotto G., Crisà E., Musto P., Gozzini A., Cavalli L., Montefusco E., Iurlo A., Russo S., Cedrone M., Rossi A.R., Pregno P., Endri M., Spadea A., Molica M., Giglio G., Celesti F., Sorà F., Storti S., D’Addosio A., Cambrin G.R., Isidori A., Sica S., Abruzzese E., Specchia G., Rosti G., Alimena G.

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.

LEUKEMIA RES 2014; 38(10): 1173-1176.

________________________________________

Lussana F., Carobbio A., Randi M.L., Elena C., Rumi E., Finazzi G., Bertozzi I., Pieri L., Ruggeri M., Palandri F. , Polverelli N., Elli E., Tieghi A., Iurlo A., Ruella M., Cazzola M. , Rambaldi A., Vannucchi A.M., Barbui T.

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

BRIT J HAEMATOL 2014; 167(4): 541-546.

________________________________________

Colombo M. , Thummler K., Mirandola L., Garavelli S., Todoerti K., Apicella L., Lazzari E., Lancellotti M., Platonova N., Akbar M., Chiriva-Internati M., Soutar R., Neri A.

Notch signaling drives multiple myeloma induced osteoclastogenesis.

ONCOTARGET 2014; 5(21): 10393-10406.

________________________________________

Negrini M., Cutrona G., Bassi C., Fabris S., Zagatti B., Colombo M. , Ferracin M., D’Abundo L., Saccentini E., Matis S., Lionetti M., Agnelli L., Gentile M., Recchia A.G., Bossio S., Reverberi D. , Rigolin G.M., Calin G.A., Sabbioni S., Russo G., Tassone P., Morabito F., Ferrarini M., Neri A.

microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters.

CLIN CANCER RES 2014; 20(15): 4141-4153.

________________________________________

Raimondi L., Amodio N., Di Martino M.T., Altomare E., Leotta M., Caracciolo D., Gulla A., Neri A., Taverna S., D’Aquila P., Alessandro R., Giordano A., Tagliaferri P., Tassone P.

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.

ONCOTARGET 2014; 5(10): 3039-3054.

________________________________________

Leotta M., Biamonte L., Raimondi L., Ronchetti D., Martino M.T., Botta C.,  Leone E., Pitari M.R., Neri A., Giordano A., Tagliaferri P., Tassone P., Amodio N.

A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.

J CELL PHYSIOL 2014; 229(12): 2106-2116.

________________________________________

Cottini F., Hideshima T., Xu C., Sattler M., Dori M., Agnelli L., Ten Hacken E., Bertilaccio M.T., Antonini E., Neri A., Ponzoni M., Marcatti M., Richardson P.G., Carrasco R., Kimmelman A.C., Wong K.K., Caligaris-Cappio F., Blandino G., Kuehl W.M., Anderson  K.C., Tonon G.

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

NAT MED 2014; 20(6): 599-606.

________________________________________

Gentile G., Cutrona G., Mosca L., Matis S., Fabris S., Lionetti M., Ilariucci F., Zupo S., Musolino C., Levato L., Molica S., Di Raimondo F., Vincelli I., Di Rienzo N., Pesce E.A., Angrilli F., Federico M., Neri A., Ferrarini M., Morabito F.

Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.

AM J HEMATOL 2014; 89(7): 743-750.

________________________________________

Falisi E., Novella E., Visco C., Guercini N., Maura F., Giaretta I., Pomponi F., Nichele I., Finotto S., Montaldi A., Neri A., Rodeghiero F.

B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities.

HEMATOL ONCOL 2014; 32(1): 22-30.

________________________________________

Ronchetti D., Tuana G., Rinaldi A., Agnelli L., Cutrona G., Mosca L., Fabris S., Matis S., Colombo M. , Gentile M., Grazia Recchia A., Kwee I., Bertoni F., Morabito F., Ferrarini M., Neri A.

Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia.

GENE CHROMOSOME CANC 2014; 53(3): 264-273.

________________________________________

Verdelli D., Nobili L., Todoerti K., Mosca L., Fabris S., D’Anca M., Pellegrino E., Piva R., Inghirami G., Capelli C., Introna M., Baldini L., Chiaramonte R., Lombardi L., Neri A.

Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.

GENE CHROMOSOME CANC 2014; 53(2): 154-167.

________________________________________

Barcellini W., Fattizzo B., Zaninoni A., *Radice T., Nichele I., Di Bona E., Lunghi M., Tassinari C., Alfinito F., Ferrari A., Leporace A.P., Niscola P., Carpenedo M., Boschetti C., Revelli N., Villa M.A., Consonni D., Scaramucci L., De Fabritiis P., Tagariello G., Gaidano G., Rodeghiero F., Cortelezzi A., Zanella A.

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.

BLOOD 2014; 124(19): 2930-2936.

________________________________________

Martinelli I., De Stefano V., Carrobbio A., Randi M.L., Santarossa C., Rambaldi A., Finazzi M.C., Cervantes F., Arellano Rodrigo E., Rupoli S., Canafoglia L., Tieghi A., Facchini L., Betti S., Vannucchi A.M., Pieri L., Cacciola R., Cacciola E., Cortelezzi A., Iurlo A., Pogliani EM., Elli E.M., Spadea A., Barbui T.

Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.

AM J HEMATOL 2014; 89(11): E200-E205.

________________________________________

Iurlo A., Gianelli U., Beghini A., Spinelli O., Orofino N., Lazzaroni F., Cambiaghi S., Intermesoli T., Rambaldi A., Cortelezzi A.

Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.

ONCOTARGET 2014; 5(13): 4665-4670.

________________________________________

Visco C., Barcellini W., Maura F., Neri A., Cortelezzi A., Rodeghiero F.

Autoimmune cytopenias in chronic lymphocytic leukemia.

AM J HEMATOL 2014; 89(11): 1055-1062.

________________________________________

Hoxha M., Fabris S., Agnelli L., Bollati V., Cutrona G., Matis S., Recchia A.G., Gentile M., Cortelezzi A., Morabito F., Bertazzi P.A., Ferrarini M., Neri A.

Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia.

GENE CHROMOSOME CANC 2014; 53(7): 612-621.

Back to top